Emerging Biomarkers in Alcohol Associated Liver Disease

Posted: February 7, 2023

It’s Not Just Support. It’s Solutions.


Non-Invasive Biomarkers for Alcohol Associated Liver Disease Studies

Biomarkers of cell death and regeneration, inflammation, and immune response become useful tools as new potential Alcohol Associated Liver Disease (ALD) and Alcohol Associated Hepatitis (AH) treatment options are investigated. Serum biomarkers can provide valuable insights into:

  • Disease severity and progression in ALD and AH research studies
  • Mechanisms involved in ALD and AH pathogenesis

cell death, complement activation, liver regeneration fibrosis, immune response, ccCK18, M30 Apoptsosense, CK18, M65 EpiDeath, SCD163, NGAL, L-FABP

DiaPharma has the tools for ALD Research.

Measure hepatocyte apoptosis and/or necrosis with our Cytokeratin 18/Keratin 18 (CK18/K18) biomarkers:

Additional Biomarkers of Interest:

Also, ask us about the first commercial immunoassay kit to measure NETs in human plasma or serum on the market. Perfect for sepsis studies.

Visit diapharma.com for our comprehensive portfolio including biomarkers for Nonalcoholic Fatty Liver Disease (NAFLD) / Nonalcoholic Steatohepatitis (NASH) and Drug Induced Liver Injury (DILI).

All products are for research use only in the U.S. and Canada. Not for use in diagnostic procedures.


liver disease research Nonalcoholic Fatty Liver Disease (NAFLD) / Nonalcoholic Steatohepatitis (NASH), Alcoholic Hepatitis (AH), Drug Induced Liver Injury (DILI)


It’s Not Just Support. It’s Solutions.

Over 25 years of scientific expertise,

with support just a call or click away.

Diapharma Jen Mike


DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069

Technical Support: 1.800.447.3846